| April
2004
Oxford
Optronix receives ISO 9001:2000 and ISO 13485:2003 certification.
Following
a recent audit of the quality management system by AMTAC
Certification Services, Oxford Optronix has received
certification to ISO 9001:2000 and ISO 13485:2003. Both
of these standards make use of a process based approach
to quality and business management.
ISO
13485:2003, entitled Medical Devices – Quality
Management Systems, is the very latest process based
system for medical device manufacturers. It replaces
EN 46001, which has been withdrawn. The decision to
move straight to a process based system for medical
devices rather than use the intermediate step of certification
to ISO 13485:2001 (based upon ISO 9001:1994) was taken
so that all parts of the business could immediately
benefit from process based management.
In
a process based system activities and related resources
are linked to form a process. At Oxford Optronix we
have nine processes that interact and form our business.
By determining how our processes interact we are able
manage them to ensure that the whole system is focused
on meeting the needs of our customers. We can measure
process performance and effectiveness which in turn
allows us to make continual improvements to the processes
and ultimately the business.
back
to top
March
2003
Oxford
Optronix Ltd. licenses a novel tissue oxygen monitoring
technology developed by VCURES.
Oxford
Optronix Ltd., a world leader in tissue oxygen and blood
flow monitoring, has licensed from VCU a novel tissue
oxygen monitoring technology developed by VCURES (www.vcures.org).
The technology developed by VCURES uses a novel combination
of spectroscopy techniques to non-invasively determine
the balance of tissue oxygen delivery and utilization.
The technology is envisioned to become a valuable tool
in the assessment of the critically ill or injured patient
for both diagnostic purposes and as a guide to treatment.
Currently, the major tools used in early assessment
of severely ill or injured patients is the use of blood
pressure and heart rate which are known to be notoriously
deceiving and incapable of providing healthcare providers
a true picture of tissue health. This new technology
may have particular application in the decision making
process when assessing mass casualty situations. Additionally,
it may also assist doctors in developing better criteria
for determining the need for blood transfusions and
in assessing individual organ health during surgeries.
Oxford Optronix Ltd. CEO Dr. Andrew Obeid states “We
are very excited about the opportunity to work with
VCURES which has clearly established itself as an innovative
leader in the study of shock and its treatment. One
of the most outstanding features of this group is that
they are bringing together clinicians, basic scientists
and engineers to address critical and complex problems
associated with acute illness and injury”.
Oxford
Optronix Ltd. and VCURES will work aggressively to develop
a clinical prototype for testing in the near future.
For more information, please contact Oxford
Optronix Ltd or VCURES.
back
to top
May
2002
Announcing
ColCount™
An
automated counter of mammalian cell colonies ColCount™
is a fully automated, laboratory bench-top system developed
specifically for counting mammalian cell colonies resulting
from the clonogenic cell-survival assay.
ColCount™
will be of particular interest to Cell and Radiation
Biologists looking for a powerful, versatile and cost-effective
alternative to labour-intensive manual counting methods.
back
to top
October
2001
OxyFlo™
blood perfusion monitor receives CE-Marking
Introducing
'OxyFlo C', where 'C' stands for 'Clinical'.
Oxford
Optronix proudly announces that our proven and popular
multi-channel blood perfusion monitor is now CE-marked
for clinical use in Europe.
Ground-breaking
features of the new OxyFlo C™ include the introduction
of a unique range of re-usable needle and tissue surface
sensors that can be sterilized up to 20 times using standard
hospital autoclave sterilizers. For the user this means
improved patient safety, ease-of-use and value for money.
back
to top
January
2001
Announcing
OxyLab™ - entry-level Tissue Monitoring
Oxford
Optronix proudly presents OxyLab™, an entry-level,
single channel Tissue Monitoring System specifically
developed for the laboratory and experimental user.
OxyLab™
is based on the established, award winning, fibre-optic
technology of our professional, multi-channel OxyLite™
systems.
back
to top
|
